Arnon Lavie, PhD, University of Illinois at Chicago

Arnon Lavie, PhD
Arnon Lavie, PhD

The Lavie laboratory strives to understand at the molecular level the function and workings of medicinally relevant enzymes and proteins. They address questions such as those that relate to substrate (or drug) specificity, enzymatic mechanisms, and the determinants of protein-protein recognition and regulation. They use a range of tools including protein X-ray crystallography, molecular biology, and enzyme kinetics.

The Investigator's Annexe Part of The Investigator's Annexe program.

Products

References

  1. Schalk AM, Nguyen HA, Rigouin C, Lavie A. Identification and structural analysis of an L-asparaginase enzyme from guinea pig with putative tumor cell killing properties. J Biol Chem. 2014 Nov 28;289(48):33175-86. doi: 10.1074/jbc.M114.609552. Epub 2014 Oct 15.
  2. Neschadim A, Wang JC, Sato T, Fowler DH, Lavie A, Medin JA. Cell fate control gene therapy based on engineered variants of human deoxycytidine kinase. Mol Ther. 2012 May;20(5):1002-13. doi: 10.1038/mt.2011.298. Epub 2012 Jan 24.
  3. Hazra S, Sabini E, Ort S, Konrad M, Lavie A. Extending thymidine kinase activity to the catalytic repertoire of human deoxycytidine kinase. Biochemistry. 2009 Feb 17;48(6):1256-63. doi: 10.1021/bi802062w.
  4. Sabini E, Hazra S, Konrad M, Lavie A. Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides. J Med Chem. 2007 Jun 28;50(13):3004-14. Epub 2007 May 27.
  5. Sabini E, Ort S, Monnerjahn C, Konrad M, Lavie A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat Struct Biol. 2003 Jul;10(7):513-9.